ES2136583T1 - Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa. - Google Patents

Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa.

Info

Publication number
ES2136583T1
ES2136583T1 ES97910794T ES97910794T ES2136583T1 ES 2136583 T1 ES2136583 T1 ES 2136583T1 ES 97910794 T ES97910794 T ES 97910794T ES 97910794 T ES97910794 T ES 97910794T ES 2136583 T1 ES2136583 T1 ES 2136583T1
Authority
ES
Spain
Prior art keywords
procedures
compositions
expression
supply
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES97910794T
Other languages
English (en)
Inventor
Tattanahalli L Nagabhushan
Deba P Saha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of ES2136583T1 publication Critical patent/ES2136583T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A PROCEDIMIENTOS Y COMPOSICIONES PARA LA EXPRESION ESPECIFICA EN UN TEJIDO DE INTERFEROS ALFA, CON FINES TERAPEUTICOS.
ES97910794T 1996-10-18 1997-10-16 Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa. Pending ES2136583T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73381596A 1996-10-18 1996-10-18

Publications (1)

Publication Number Publication Date
ES2136583T1 true ES2136583T1 (es) 1999-12-01

Family

ID=24949214

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97910794T Pending ES2136583T1 (es) 1996-10-18 1997-10-16 Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa.

Country Status (20)

Country Link
EP (2) EP0932679A1 (es)
JP (2) JP2001502540A (es)
KR (1) KR20000049243A (es)
AR (1) AR013618A1 (es)
AU (1) AU4808097A (es)
BR (1) BR9712362A (es)
CA (1) CA2269100A1 (es)
CZ (1) CZ131699A3 (es)
DE (1) DE932679T1 (es)
ES (1) ES2136583T1 (es)
HU (1) HUP9904219A2 (es)
ID (1) ID24500A (es)
IL (1) IL129387A0 (es)
NO (1) NO991839L (es)
NZ (1) NZ335134A (es)
PL (1) PL332856A1 (es)
SK (1) SK50699A3 (es)
TR (1) TR199901190T2 (es)
WO (1) WO1998017801A1 (es)
ZA (1) ZA979295B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912925D0 (en) * 1999-06-03 1999-08-04 Angeletti P Ist Richerche Bio Adenoviral vectors encoding interferon and their use in gene therapy
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
ES2363912T3 (es) 2003-12-10 2011-08-19 Canji, Inc. Procedimientos y composiciones para el tratamiento de tumores resistentes a interferon.
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
KR101470472B1 (ko) 2006-09-14 2014-12-09 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
ES2439954T3 (es) * 2007-02-23 2014-01-27 Her Majesty The Queen, In Right Of Canada, As Represented By The Minister Of National Defence Vectores víricos recombinantes para la prevención y la protección contra la infección por alfavirus
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
CA2802726A1 (en) 2010-06-15 2011-12-22 Medgenics Medical Israel Ltd. Long lasting drug formulations
AU2018246292A1 (en) 2017-03-31 2019-10-10 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (NMSC)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238778C2 (de) * 1992-11-12 1995-11-02 Max Delbrueck Centrum Vektor zur Expression von therapeutisch relevanten Genen
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
PT797676E (pt) * 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
DE4407859C1 (de) * 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
IL129387A0 (en) 2000-02-17
JP2001502540A (ja) 2001-02-27
JP2008301832A (ja) 2008-12-18
KR20000049243A (ko) 2000-07-25
NO991839D0 (no) 1999-04-16
DE932679T1 (de) 2000-03-09
EP1591528A3 (en) 2005-11-16
ID24500A (id) 2000-07-20
ZA979295B (en) 1998-04-20
HUP9904219A2 (hu) 2000-12-28
AR013618A1 (es) 2001-01-10
PL332856A1 (en) 1999-10-25
CA2269100A1 (en) 1998-04-30
AU4808097A (en) 1998-05-15
WO1998017801A1 (en) 1998-04-30
EP1591528A2 (en) 2005-11-02
NZ335134A (en) 2001-05-25
TR199901190T2 (xx) 1999-07-21
NO991839L (no) 1999-06-15
BR9712362A (pt) 1999-08-31
CZ131699A3 (cs) 1999-07-14
EP0932679A1 (en) 1999-08-04
SK50699A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
ES2136583T1 (es) Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa.
PL328947A1 (en) Isolated dimetric protein capable to activate the alpha fibroblasts and application thereof
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
HN1998000132A (es) Combinaciones terapeuticas
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
YU79393A (sh) Terapeutska kombinacija
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
HN1998000124A (es) Terapia de combinacion
ES2153468T3 (es) Preparaciones cosmeticas y/o farmaceuticas con sensacion cutanea mejorada.
HN1998000088A (es) Tratamiento de resistencia a la insulina
ATE419268T1 (de) Haemasterlin analoge
HN1998000091A (es) Inhibidores de la farnesil transferasa tratamiento del cancer.
SE9602822D0 (sv) New receptor
ES2174103T3 (es) Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
DK0977871T3 (da) Neurotrypsin
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
ATE494375T1 (de) Frazzled nukleotidsequenzen, expressions- produkte, zusammensetzungen und verwendungen
TR199802504T2 (xx) N�rotoksik yaralanmalar�n tedavisi i�in bukminsterflirin kullan�lmas�.
NO960749D0 (no) Rekombinante Cladosporium herbarum allergener
ES2179908T3 (es) Acidos sacarosamonocarboxilicos acilados.
ES2161698T3 (es) Anticuerpos especificos contra plaquetas activadas, su produccion y su utilizacion en la diagnosis y terapia.
AR027238A1 (es) Peptido relacionado a condromodulina-i